With much-awaited approval of biosimilar interchangeability by FDA, the dynamics in the much nascent US biosimilars market is about to change with long-lasting price competition.
The report Global Biosimilar Market by Classes (Insulin, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte-Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb) and Interferon (IFN) & Markets (Developed & Emerging) - Industry Outlook 2020 provides an in-depth analysis of global biosimilars market focusing on key segments detailing approved and upcoming biosimilar products. Market outlook for aforementioned biosimilar classes has been provided for the period 2017-20.
The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities at the global and regional level.
The report has been segmented as following:
Market Segmentation by Classes:
- Erythropoietin (EPO)
- Human Growth Hormone (HGH)
- Granulocyte - Colony Stimulating Factor (G-CSF)
- Monoclonal Antibody (mAb)
- Interferon (IFN)
Market Segmentation by Geography:
- Developed Markets - Europe and the US
- Emerging Markets - China & India
- Dong-A Pharmaceutical Co., Ltd.
For more information about this report visit http://www.researchandmarkets.com/research/zg4k2m/global_biosimilar
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-biosimilar-market-industry-outlook-2017-2020-focus-on-insulin-epo-hgh-g-csf-mab--ifn---research-and-markets-300406304.html
SOURCE Research and Markets